Flumazenil
| 159px | |
| 159px | |
| Systematic (IUPAC) name | |
|---|---|
|
ethyl 12-fluoro- 8-methyl- 9-oxo- 2,4,8- triazatricyclo [8.4.0.02,6] tetradeca- 1(10),3,5,11,13- pentaene- 5-carboxylate | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Biological half-life |
7-15 min (initial) 20-30 min (brain) 40-80 min (terminal) |
| Excretion |
Urine 90-95% Feces 5-10% |
| Identifiers | |
| CAS Number | 78755-81-4 |
| ATC code | V03AB25 (WHO) |
| PubChem | CID 3373 |
| DrugBank | APRD00974 |
| ChemSpider | 3256 |
| Synonyms | ethyl 8-fluoro- 5,6-dihydro- 5-methyl- 6-oxo- 4H- imidazo [1,5-a] [1,4] benzodiazepine- 3-carboxylate |
| Chemical data | |
| Formula | C15H14FN3O3 |
| Molar mass | 303.288 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Flumazenil (also known as flumazepil, code name Ro 15-1788, trade names Anexate, Lanexat, Mazicon, Romazicon) is a benzodiazepine antagonist.
It was introduced in 1987 by Hoffmann-La Roche under the trade name Anexate.
Contents
Uses
Flumazenil is of benefit in patients who become excessively drowsy after benzodiazepines are used for either diagnostic or therapeutic procedures.[1]
It has been used as an antidote in the treatment of benzodiazepine overdoses.[1] It reverses the effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site on the GABAA receptor. There are many complications that must be taken into consideration when used in the acute care setting.[1]
It has been found to be effective in overdoses of non-benzodiazepine sleep enhancers, namely zolpidem and zaleplon.[2]
It has also been used in hepatic encephalopathy, though results have been mixed.[3][4]
The onset of action is rapid and usually effects are seen within one to two minutes. The peak effect is seen at six to ten minutes. The recommended dose for adults is 200 μg every 1–2 minutes until the effect is seen, to a maximum of 3 mg per hour. It is available as a clear, colourless solution for intravenous injection, containing 500 μg in 5 mL.
Many benzodiazepines (including midazolam) have longer half-lives than flumazenil. Therefore, repeat doses of flumazenil may be required to prevent recurrent symptoms of overdosage once the initial dose of flumazenil wears off. It is hepatically metabolised to inactive compounds which are excreted in the urine. Subjects who are physically dependent on benzodiazepines may suffer benzodiazepine withdrawal symptoms, including seizure, upon administration of flumazenil.
It is not recommended for routine use in those with a decreased level of consciousness.[5]
PET radioligand
Radiolabeled with the radioactive isotope carbon-11 flumazenil may be used as a radioligand in neuroimaging with positron emission tomography to visualize the distribution of GABAA receptors in the human brain.[6]
Clinical pharmacology
Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA / benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in humans.
Flumazenil does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.
In animals pretreated with high doses of benzodiazepines over several weeks, Flumazenil injection elicited symptoms of benzodiazepine withdrawal, including seizures. A similar effect was seen in adult human subjects.
Pharmacodynamics
Intravenous Flumazenil has been shown to antagonize sedation, impairment of recall, psychomotor impairment and ventilatory depression produced by benzodiazepines in healthy human volunteers.
The duration and degree of reversal of sedative benzodiazepine effects are related to the dose and plasma concentrations of Flumazenil.
Chemistry
Gerecke, M.; Hunkeler, W.; Kyburz, E.; Mohler, H.; Pieri, L.; Pole, P.; 1982, U.S. Patent 4,316,839.
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />Other
- Romazicon product information, Roche USA
External links
- Flumazenil drug label/data at Daily Med from U.S. National Library of Medicine, National Institutes of Health.
fr:Flumazénil it:Flumazenil hu:Flumazenil pl:Flumazenil pt:Flumazenil sq:Flumazenil
sv:Flumazenil- ↑ 1.0 1.1 1.2 Goldfrank, Lewis R. (2002). Goldfrank's toxicologic emergencies. New York: McGraw-Hill Medical Publ. Division. ISBN 0-07-136001-8.
- ↑ Nelson, Lewis H.; Flomenbaum, Neal; Goldfrank, Lewis R.; Hoffman, Robert Louis; Howland, Mary Deems; Neal A. Lewin (2006). Goldfrank's toxicologic emergencies. New York: McGraw-Hill, Medical Pub. Division. ISBN 0-07-147914-7.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Als-Nielsen B, Gluud LL, Gluud C (2004). "Benzodiazepine receptor antagonists for hepatic encephalopathy". Cochrane Database Syst Rev (2): CD002798. doi:10.1002/14651858.CD002798.pub2. PMID 15106178.
- ↑ Wood, Lawrence D. H.; Hall, Jesse B.; Schmidt, Gregory D. 1952 (2005). Principles of critical care. McGraw-Hill Professional. ISBN 0-07-141640-4.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Antidotes
- Benzodiazepines
- Organofluorides
- GABA antagonists
- Convulsants
- Anxiogenics
- Carboxylate esters
- Lactams
- Hoffmann-La Roche
- 2Fix
- CS1 maint: Multiple names: authors list
